SANTA MONICA, CA / ACCESSWIRE / September 17, 2020 / BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for liver disease, today announced the pricing of an underwritten public offering of 1,565,200 shares of Class A common stock at a pu...

Hariri, Gorlin, and Rogich to Contribute Their Tremendous Industry Insights and Stature

Novel BIV201 Formulation Shows Significant Improvements Over Industry TerlipressinPrefilled Syringe May Significantly Extend Market Protection Beyond Orphan Drug Exclusivity